tiprankstipranks
Trending News
More News >

Predictive Oncology Finalizes Stock Exchange Purchase Agreement

Story Highlights
Predictive Oncology Finalizes Stock Exchange Purchase Agreement

Don’t Miss TipRanks’ Half-Year Sale

Predictive Oncology ( (POAI) ) has provided an announcement.

Predictive Oncology has entered into a Stock Exchange Purchase Agreement (SEPA) with an accredited investor, allowing the issuance and sale of shares of Common Stock. This transaction is conducted under the exemptions from registration requirements of the Securities Act, potentially impacting the company’s financial operations and investor relations.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Spark’s Take on POAI Stock

According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.

The overall stock score is heavily impacted by poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. Regulatory challenges and the potential for Nasdaq delisting exacerbate the company’s risk profile.

To see Spark’s full report on POAI stock, click here.

More about Predictive Oncology

Average Trading Volume: 153,966

Technical Sentiment Signal: Strong Sell

Current Market Cap: $7.59M

For detailed information about POAI stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1